Latest News

Latest News

Physical Activity and Dementia: The Evidence Base Is Uneven

Physical Activity and Dementia: The Evidence Base Is Uneven

The link between physical activity and dementia depends on where that activity happens, according to a meta analysis of 74 studies covering more than four million adults. Leisure time exercise was associated with a lower risk of dementia, while activity undertaken at...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Rethinking Biomedical Research in the Age of AI

Rethinking Biomedical Research in the Age of AI

The paradox of modern biomedical research Biomedical research has never generated so much knowledge, and researchers have never struggled so much to keep pace with it. PubMed now indexes more than 40 million references drawn from roughly 26,000 journals[1]....

read more
Retatrutide Black Market: Lilly Sues Six US Sellers

Retatrutide Black Market: Lilly Sues Six US Sellers

Eli Lilly has filed six lawsuits against United States companies. It accuses them of selling illegal versions of its experimental obesity drug, which remains in Phase 3 trials. The retatrutide black market runs through peptide websites, medical spas and wellness...

read more
Beyond Tolvaptan: The Next Generation of ADPKD Therapies

Beyond Tolvaptan: The Next Generation of ADPKD Therapies

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...

read more
What Trauma Taught Me That Medical School Never Did

What Trauma Taught Me That Medical School Never Did

Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...

read more
CAR-T Therapy Explained: A Plain-English Guide

CAR-T Therapy Explained: A Plain-English Guide

CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...

read more
Weekly News Roundup | 17 August 2026

Weekly News Roundup | 17 August 2026

Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...

read more
LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...

read more
Rethinking Biomedical Research in the Age of AI

Rethinking Biomedical Research in the Age of AI

The paradox of modern biomedical research Biomedical research has never generated so much knowledge, and researchers have never struggled so much to keep pace with it. PubMed now indexes more than 40 million references drawn from roughly 26,000 journals[1]....

read more
Retatrutide Black Market: Lilly Sues Six US Sellers

Retatrutide Black Market: Lilly Sues Six US Sellers

Eli Lilly has filed six lawsuits against United States companies. It accuses them of selling illegal versions of its experimental obesity drug, which remains in Phase 3 trials. The retatrutide black market runs through peptide websites, medical spas and wellness...

read more
Beyond Tolvaptan: The Next Generation of ADPKD Therapies

Beyond Tolvaptan: The Next Generation of ADPKD Therapies

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...

read more
What Trauma Taught Me That Medical School Never Did

What Trauma Taught Me That Medical School Never Did

Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...

read more
CAR-T Therapy Explained: A Plain-English Guide

CAR-T Therapy Explained: A Plain-English Guide

CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...

read more
Weekly News Roundup | 17 August 2026

Weekly News Roundup | 17 August 2026

Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...

read more
LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Clinical Trials Roundup | 14 Aug 2026

Clinical Trials Roundup | 14 Aug 2026

Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...

read more
Kidney Care’s $2.5 Billion Timing Problem

Kidney Care’s $2.5 Billion Timing Problem

Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...

read more
Beyond Weight Loss: What Emerging GLP-1 Research Reveals

Beyond Weight Loss: What Emerging GLP-1 Research Reveals

For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...

read more
GLP-1 Side Effects: What the Evidence Actually Says

GLP-1 Side Effects: What the Evidence Actually Says

An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...

read more

Further News

Clinical Trials Roundup | 14 Aug 2026

Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...

From Laboratory to Market: Risk Planning for Life Science Companies

The UK life sciences sector is entering an important phase of growth. The Government's Life Sciences Sector Plan sets an ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third globally by 2035. It also reports that the sector...

Biopharma VC Funding in H1 2026: Megarounds Mask an Early-Stage Squeeze

Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data...

Organ Digital Twins: Inside Imperial College London’s Research

Organ digital twins have moved from mathematical curiosity to funded national priority. Imperial College London now sits close to the centre of that shift. Researchers there have built more than 3,800 anatomically accurate virtual hearts. They have also begun an NHS...

Glass Slides to AI: Digital Pathology Can Transform Cancer Care in the NHS

Every year, millions of pathology slides are produced in the UK, most still examined manually under a microscope. This century-old process, though reliable, is no longer fit for purpose. Pathology departments face mounting workforce pressures, with 78% pathologists...

Kidney Care’s $2.5 Billion Timing Problem

Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...

Blood Supplies Set For Vital Boost as Donation Rules Are Updated

Long-running campaign removes unnecessary barrier for blood donors, a victory for both patients and the blood donation service* Patients receiving acupuncture from appropriately qualified practitioners will no longer have to wait four months before donating blood,...

In Vivo CAR-T Therapy: The Next Frontier in Cell Therapy Explained

In vivo CAR-T therapy has travelled from laboratory concept to clinical reality faster than almost any modality in recent memory. Conventional cell therapy collects a patient’s T cells, engineers them in a specialist facility and returns them weeks later. The in vivo...

Cutting Through the Noise: How AI/ML Can Guide Target Selection for Vaccines

Modern vaccine research has entered an era of colossal data abundance. Researchers can now examine complete pathogen genomes and proteomes, measure hundreds of thousands of antigen-specific antibody responses, characterize immune-cell states at single-cell resolution...

Beyond Weight Loss: What Emerging GLP-1 Research Reveals

For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...

GLP-1 Side Effects: What the Evidence Actually Says

An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...

Bridging Cosmetic Science & Clinical Research: When Beauty Becomes Therapeutic

The evolving landscape of cosmetic science is increasingly defined by its convergence with clinical research, challenging long-standing distinctions between aesthetic enhancement and therapeutic intervention. Historically, cosmetics have been confined to products...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.